Company profile: Shattuck Labs
1.1 - Company Overview
Company description
- Provider of novel biologic medicines for cancer and autoimmune diseases, leveraging the ARC platform to create bi-functional fusion proteins combining immune checkpoint blockade with TNF costimulation. Pipeline includes SL-172154 (SIRPα-Fc-CD40L) in Phase 1 targeting CD47 on malignant cells and CD40 on immune cells for ovarian cancer and AML/HR-MDS, plus over 400 candidates across validated and emerging pathways.
Products and services
- SL-172154 (SIRPα-Fc-CD40L): Phase 1 bi-functional fusion protein targeting CD47 on malignant cells and CD40 on immune cells for platinum-resistant ovarian cancer and AML/HR-MDS
- Drug Pipeline: Portfolio of over 400 bi-functional fusion proteins targeting clinically validated and emerging pathways for cancer and autoimmune diseases
- ARC Platform: Bi-functional technology platform that creates fusion proteins combining immune checkpoint blockade with TNF costimulation to treat cancer and autoimmune diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Shattuck Labs
Ankyra Therapeutics
HQ: United States
Website
- Description: Provider of anchored immunotherapy for cancer treatments as a biotech company developing immunotherapy solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ankyra Therapeutics company profile →
PhosImmune
HQ: United States
Website
- Description: Provider of clinical-stage therapeutic cancer vaccines enabled by a library of unique, aberrantly phosphorylated tumor antigens (PTAs) directly implicated in metastasis, addressing the need for high-quality tumor antigens for use in new and more effective cancer vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhosImmune company profile →
Vaccinex
HQ: United States
Website
- Description: Provider of therapeutic antibody discovery and development focused on neurodegeneration, oncology and autoimmune diseases. Offers Pepinemab, a monoclonal antibody targeting SEMA4D in clinical trials for cancers, Huntington's and Alzheimer's; ActivMAb, a platform for antibody discovery against complex antigens; and VX5/5261, a CXCL13-targeting antibody in preclinical development for rheumatoid arthritis and multiple sclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaccinex company profile →
Ducentis Biotherapeutics
HQ: United Kingdom
Website
- Description: Provider of pre-clinical-stage development of novel therapies for inflammation and autoimmune disease, targeting the CD200/CD200R axis to impart deactivating signals to activated immune cells in both innate and adaptive immunity, with potential therapeutic targets including transplant rejection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ducentis Biotherapeutics company profile →
Carisma Therapeutics
HQ: United States
Website
- Description: Provider of chimeric antigen receptor macrophage therapies for solid tumors, including CT-0525, an ex vivo gene-modified autologous CAR-Monocyte therapy targeting HER2-overexpressing solid tumors in Phase 1, and in vivo macrophage-targeted therapies for solid tumors via a partnership with Moderna, with a lead candidate targeting an unspecified antigen; also pursuing early R&D in liver fibrosis using its macrophage and monocyte engineering platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carisma Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Shattuck Labs
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Shattuck Labs
2.2 - Growth funds investing in similar companies to Shattuck Labs
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Shattuck Labs
4.2 - Public trading comparable groups for Shattuck Labs
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →